Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proxyfan SCHEMBL29462311 | 0.93 | HRH3 (0.87) | HRH3HRH4 | |
| SCHEMBL2536900 | 0.80 | HRH3 (0.93) | HRH3HRH4TAAR1 | |
| SCHEMBL224745 | 0.77 | TAAR1 (1.00) | HRH3HRH4TAAR1 | |
| SCHEMBL194703 | 0.75 | HRH3 (0.71) | HRH3HRH4 | |
| SCHEMBL4069939 | 0.74 | TDP1 (0.64) | HRH3HRH4 | |
| SCHEMBL4217229 | 0.73 | HRH3 (0.58) | HRH3HRH4 | |
| SCHEMBL4769249 | 0.73 | HRH4 (0.57) | HRH3HRH4 | |
| SCHEMBL18536735 | 0.72 | HRH3 (0.57) | HRH3HRH4TAAR1 | |
| SCHEMBL2741614 | 0.72 | ADRA1A (0.68) | HRH3HRH4TAAR1 | |
| SCHEMBL8964986 | 0.72 | HRH3 (0.79) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449144-B2 | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-10206985-B2 | WT1 peptide cancer vaccine composition for mucosal administration | NITTO DENKO CORPORATION (JP) | 2019-02-19 | — | — | US | disclosed |
| US-10195258-B2 | Tape preparation of WT1 peptide cancer vaccine for transdermal administration | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20170224813-A1 | VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL | NITTO DENKO CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20150080380-A1 | Therapeutic Uses | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-20150080380-A1 | Therapeutic Uses | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220058-A1 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220063-A1 | VACCINE COMPOSITION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220105-A1 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220105-A1 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | HRH3 4254/4885HRH4 4547/4885TAAR1 2767/4885 |
| US-10206985-B2 | WT1 peptide cancer vaccine composition for mucosal administration | MUC1, TAP1, MICA | HRH3 3667/4885HRH4 4151/4885TAAR1 3709/4885 |
| US-10449144-B2 | WT1 peptide cancer vaccine composition for transdermal administration | TAP1, TAP2, MICA | HRH3 3871/4885HRH4 4045/4885TAAR1 2639/4885 |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MUC1 | HRH3 3261/4885HRH4 3271/4885TAAR1 2093/4885 |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | ERBB2, EGFR, ERBB3 | HRH3 1087/4885HRH4 644/4885TAAR1 1901/4885 |
| US-20140220058-A1 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION | CD69, TSLP, MUC1 | HRH3 369/4885HRH4 306/4885TAAR1 493/4885 |
| US-10195258-B2 | Tape preparation of WT1 peptide cancer vaccine for transdermal administration | TAP1, TAP2, MICA | HRH3 4254/4885HRH4 4547/4885TAAR1 2767/4885 |
| US-20150080380-A1 | Therapeutic Uses | HRH3, HRH4, HRH2 | HRH3 1/4885HRH4 2/4885TAAR1 190/4885 |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | HRH3 3871/4885HRH4 4045/4885TAAR1 2639/4885 |
| US-20170224813-A1 | VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL | BAX, GZMB, BCL2 | HRH3 3284/4885HRH4 3713/4885TAAR1 4520/4885 |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, ERBB2, TLR5 | HRH3 486/4885HRH4 394/4885TAAR1 2673/4885 |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, TAP1, MICA | HRH3 3667/4885HRH4 4151/4885TAAR1 3709/4885 |
| US-20140220063-A1 | VACCINE COMPOSITION | MYD88, IRF3, CD14 | HRH3 3420/4885HRH4 4295/4885TAAR1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.